JP2021530560A5 - - Google Patents

Info

Publication number
JP2021530560A5
JP2021530560A5 JP2021521945A JP2021521945A JP2021530560A5 JP 2021530560 A5 JP2021530560 A5 JP 2021530560A5 JP 2021521945 A JP2021521945 A JP 2021521945A JP 2021521945 A JP2021521945 A JP 2021521945A JP 2021530560 A5 JP2021530560 A5 JP 2021530560A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521945A
Other languages
English (en)
Japanese (ja)
Other versions
JP7348705B2 (ja
JP2021530560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040690 external-priority patent/WO2020010309A1/en
Publication of JP2021530560A publication Critical patent/JP2021530560A/ja
Publication of JP2021530560A5 publication Critical patent/JP2021530560A5/ja
Application granted granted Critical
Publication of JP7348705B2 publication Critical patent/JP7348705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521945A 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤 Active JP7348705B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US62/694,918 2018-07-06
US201962827573P 2019-04-01 2019-04-01
US62/827,573 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (3)

Publication Number Publication Date
JP2021530560A JP2021530560A (ja) 2021-11-11
JP2021530560A5 true JP2021530560A5 (enExample) 2022-07-13
JP7348705B2 JP7348705B2 (ja) 2023-09-21

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521945A Active JP7348705B2 (ja) 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤

Country Status (14)

Country Link
US (2) US11401246B2 (enExample)
EP (1) EP3817816A1 (enExample)
JP (1) JP7348705B2 (enExample)
KR (1) KR102865323B1 (enExample)
CN (1) CN112399873B (enExample)
AU (1) AU2019297523B2 (enExample)
BR (1) BR112021000050A2 (enExample)
CO (1) CO2021001277A2 (enExample)
IL (1) IL279952B2 (enExample)
MX (1) MX2021000051A (enExample)
PE (1) PE20210859A1 (enExample)
SA (1) SA521420951B1 (enExample)
SG (1) SG11202012930RA (enExample)
WO (1) WO2020010309A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012930RA (en) 2018-07-06 2021-01-28 Orfan Biotech Inc Triazole glycolate oxidase inhibitors
AU2020376792B2 (en) 2019-11-01 2025-10-02 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
ES3049309T3 (en) * 2020-01-08 2025-12-16 Cantero Therapeutics Inc Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
CA3234440A1 (en) * 2021-10-11 2023-04-20 Jonathan C. Fox 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
CN120225507A (zh) * 2022-11-25 2025-06-27 海思科医药集团股份有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
BRPI0515500A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados piridazina para inibição de estearoil-coa-desaturase
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
US20140213538A1 (en) 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
WO2016148193A1 (ja) 2015-03-19 2016-09-22 興人ライフサイエンス株式会社 植物の生長促進や根伸長促進効果且つ付加価値向上効果を有する酵母抽出物
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2019133813A1 (en) 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
WO2019165159A1 (en) 2018-02-23 2019-08-29 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
SG11202012930RA (en) 2018-07-06 2021-01-28 Orfan Biotech Inc Triazole glycolate oxidase inhibitors
WO2020257487A1 (en) 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease

Similar Documents

Publication Publication Date Title
JP2021530560A5 (enExample)
DE69122084T2 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JP2020530487A5 (enExample)
JP2021513534A5 (enExample)
JP2009534358A5 (enExample)
AR044044A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
RU2008145971A (ru) Производные 2-тиоксантина, действующие в качестве ингибиторов мро
JP2022544714A5 (enExample)
JP2009143956A5 (enExample)
JP2016510323A5 (enExample)
JP2006511587A5 (enExample)
JP2024529527A5 (enExample)
JP2014515349A5 (enExample)
JP2012526728A5 (enExample)
JP2020527175A5 (enExample)
JP2007502295A5 (enExample)
JP2019510082A5 (enExample)
JP2017506666A5 (enExample)
AR044043A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2019528259A5 (enExample)
RU2016120763A (ru) Ингибиторы респираторного синцитиального вируса
JP2016503403A5 (enExample)
RU2013157860A (ru) Производные бензотиазинтиона, способы их получения и применение
KR20080034436A (ko) 암 치료에 사용되는 티아졸 유도체 및 유사체